




**A****B**


<i>Cyp2j4</i> <sup>-/-</sup>	241-300	PGSHQTVFRNWEKLF <b>FTGKTGTLRSQEETSMLLSRRKCSQSTQRRLQVSMKKTSSAAPWTS</b>
WT	241-300	PGSHQTVFRNWEKLLFVSSMIDDHRKDWNPEEPRDFIDAFLEKEMSKYPEK-TTSFNEEN
<i>Cyp2j4</i> <sup>-/-</sup>	301-360	<b>SLREQRQHPLHCAGLCSTWPSQTKCKKKYRQRLTEESLARRGQAWPIENPCPIPMPSSM</b>
WT	301-360	LICSTLDLFFAGTETTTSTTLRWALLYMALYAEVQEKVQAEIDRVIGQKRAASLADRESMP
<i>Cyp2j4</i> <sup>-/-</sup>	361-420	<b>RCRGWATSSSP[STOP]</b>
WT	361-420	YTNAVIHEVQRMGNIIPLNVPREVAMDTTLNGFHLPGKTMVLTNLTLALHRDPKEWATPDV

**Supplementary Figure 1. A.** The comparative illustration of rat *Cyp2j4* and its human orthologue *CYP2J2* cDNA sequence and its corresponding peptide sequence in humans. The 25 bp deletion in the rat causes a premature stop codon upstream the putative heme binding site (residues 441, 444, 446, 448, 450 highlighted in grey). The frameshift deletion affects also the active site cavity identified in human *CYP2J2* with residues I127, F310, A311, T315, I375, I376 and V380 (highlighted in grey) that are in close proximity to heme, providing a restricted access of substrates through a narrow hydrophobic channel (Lafite et al. Biochemistry 2007 11;46(36)). Note that human *CYP2J2* presents stop/gain mutations (identified by 1000 Genomes), one of them being 143 bp upstream the premature rat stop codon. **B.** The amino acid sequence of wild-type (WT) and *Cyp2j4*<sup>-/-</sup> rat from 241-420 illustrating the frameshift caused at position 255. The frameshift sequence (shown in green colour) causes a stop codon at position 372.




**Supplementary Figure 2.** Expression levels of *Fn1*, *Col1a1*, *Col1a2*, *Col3a1* in primary fibroblasts derived from WT and *Cyp2j4*<sup>-/-</sup> skin (A) or lung (B) measured by qRT-PCR. Fibroblasts were cultured in either basal conditions or with addition of TGFβ (10ng/ml for 48 hours). Note the marked expression differences between basal lung-derived WT vs *Cyp2j4*<sup>-/-</sup> fibroblasts for all the tested transcripts. n=3 rats/strain were used in four replicates and the results are representative of two independent experiments.

A



B



**Supplementary Figure 3. A.** Oxygen consumption rate (OCR) in WT and *Cyp2j4*<sup>-/-</sup> BMDMs measured by extracellular flux analyser in WT and *Cyp2j4*<sup>-/-</sup> BMDMs in basal conditions (assay medium) and in conditions where 11,12 EETs (1 $\mu$ M) were added onto *Cyp2j4*<sup>-/-</sup> BMDMs. OCR measurements were taken every 10min following addition of either basal or +11,12 EETs media for a total duration of 3h (See experimental procedures for details). The experiment was repeated three times with at least 4 technical replicates each time. \*,  $P < 0.001$  when compared with WT; ns, non-significant when compared with WT.

**B.** TNF $\alpha$  levels were quantified by sandwich ELISA in WT and *Cyp2j4*<sup>-/-</sup> BMDMs in basal (untreated) and lipopolysaccharide (LPS, 100ng/ml, 12h) treated samples. \*,  $P < 0.05$  compared to WT (LPS) by nonparametric Wilcoxon signed-rank test; ns, non-significant when compared to WT (basal). The experiment was repeated four times using 4 biological replicates in duplicate.